PROMISE: Our kitties will never sit on top of content. Please turn off your ad blocker for our site.
puuuuuuurrrrrrrrrrrr
ISPE
Published: Friday, November 11, 2011 - 12:46 (ISPE: Tampa, FL) -- The International Society for Pharmaceutical Engineering (ISPE) has released Parts 1 and 2 of a new series of good practice guides on product quality lifecycle implementation (PQLI). These guides comprise the official first and second volumes of a planned series of PQLI guides, which collectively address product and process development through a quality by design approach that covers the entire product life cycle. The series uses ICH guidelines Q8 (R2)—“Pharmaceutical Development,” Q9—“Quality Risk Management,” and Q10—“Pharmaceutical Quality System” as a basis, together with other relevant ICH guidelines. “In recent years, both the industry and regulators have realized the importance of designing product quality into the process itself,” says PQLI project manager John Berridge. “Quality cannot be added during the testing phase; it must be built-in by design. The PQLI guide series gives industry personnel a road map for how to build quality into their processes, from product conception to continual improvement after the product is brought to market.” The first guide in the series, Part 1—Product Realization using QbD, Concepts and Principles, focuses on the topics of criticality, design space, and control strategy. Part 1 addresses product and process development, transfer to, and establishment of commercial manufacturing using science- and risk-based approaches. It also includes an introduction to and overview of the guide sections. The second guide, Part 2—Product Realization using QbD, Illustrative Example, presents a small molecule case study developed by the ISPE PQLI teams. The case study provides details of the application of the approaches to product and process understanding using quality risk management. Part 2 also examines many case studies in the public domain using ICH guidelines Q8 (R2), Q9, Q10, and other relevant ICH guidelines. For more information on the ISPE guide series or to order copies in either bound or electronic format, visit the ISPE website. Quality Digest does not charge readers for its content. We believe that industry news is important for you to do your job, and Quality Digest supports businesses of all types. However, someone has to pay for this content. And that’s where advertising comes in. Most people consider ads a nuisance, but they do serve a useful function besides allowing media companies to stay afloat. They keep you aware of new products and services relevant to your industry. All ads in Quality Digest apply directly to products and services that most of our readers need. You won’t see automobile or health supplement ads. So please consider turning off your ad blocker for our site. Thanks, The International Society for Pharmaceutical Engineering (ISPE) is a global nonprofit association of 22,000 pharmaceutical professionals in 90 countries who use knowledge to create high-quality, cost-effective good manufacturing practices (GMP) solutions. ISPE provides its members opportunities to develop technical knowledge, exchange practical experience within their community, enhance their professional skills, and collaborate with global regulatory agencies and industry leaders. Founded in 1980, ISPE offers online learning for a global audience. Its world headquarters are in Tampa, Florida, with offices in Brussels, Belgium, Shanghai, China, and Singapore.ISPE Releases Product Quality Lifecycle Implementation Series
Two good practice guides focus on quality by design principles and practices
Our PROMISE: Quality Digest only displays static ads that never overlay or cover up content. They never get in your way. They are there for you to read, or not.
Quality Digest Discuss
About The Author
ISPE
© 2023 Quality Digest. Copyright on content held by Quality Digest or by individual authors. Contact Quality Digest for reprint information.
“Quality Digest" is a trademark owned by Quality Circle Institute, Inc.